Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) Products under Development by Stage of Development | 7 | 1 |
| Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) Products under Development by Therapy Area | 8 | 1 |
| Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) Products under Development by Indication | 9 | 1 |
| Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) Products under Development by Companies | 12 | 2 |
| Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) Products under Development by Universities/Institutes | 14 | 2 |
| Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 1 |
| Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) Companies Involved in Therapeutics Development | 21 | 4 |
| AstraZeneca Plc | 21 | 1 |
| Bristol-Myers Squibb Company | 22 | 1 |
| Laboratoires Pierre Fabre SA | 23 | 1 |
| Xention Limited | 24 | 1 |
| Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) Drug Profiles | 25 | 6 |
| AFC-1 Drug Profile | 25 | 1 |
| BMS-919373 Drug Profile | 26 | 1 |
| F-373280 Drug Profile | 27 | 1 |
| Small Molecule to Block Kv1.5 for Atrial Fibrillation Drug Profile | 28 | 1 |
| XEND-0103 Drug Profile | 29 | 2 |
| Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) Dormant Projects | 31 | 1 |
| Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) Discontinued Products | 32 | 1 |
| Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) Featured News &Press Releases | 33 | 2 |
| Sep 01, 2014: Xention commences first phase 2 study of XEN-D0103 in atrial fibrillation | 33 | 1 |
| Mar 20, 2012: Xention Reports Positive Phase I Data For New Atrial Fibrillation Drug | 33 | 1 |
| Jul 27, 2011: Xention Initiates Phase I Clinical Trial Of XEN-D0103 | 34 | 1 |
| Appendix | 35 | 2 |
| Methodology | 35 | 1 |
| Coverage | 35 | 1 |
| Secondary Research | 35 | 1 |
| Primary Research | 35 | 1 |
| Expert Panel Validation | 35 | 1 |
| Contact Us | 35 | 1 |
| Disclaimer | 36 | 1 |